Syndax Pharmaceuticals, Inc. (SNDX) Revenue History
Annual and quarterly revenue from 2011 to present
SNDX Revenue Over Time (2011–2025)
SNDX Revenue Growth History
4 of 8 years with positive growth- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- +94.6%
- FY2017 revenue growth
- +72.8%
- FY2018 revenue growth
- -28.0%
- FY2019 revenue growth
- +0.0%
- FY2020 revenue growth
- +0.0%
- FY2021 revenue growth
- +9109.6%
- FY2022 revenue growth
- -100.0%
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- +627.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $64.9M | +223.6% |
| Q4 2025 | $68.5M | +791.7% |
| Q3 2025 | $45.9M | +267.0% |
| Q2 2025 | $38.0M | +984.5% |
| Q1 2025 | $20.0M | — |
| Q4 2024 | $7.7M | — |
| Q3 2024 | $12.5M | — |
| Q2 2024 | $3.5M | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
SNDX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
SNDX Revenue Analysis (2011–2025)
Current Revenue & Growth
As of June 23, 2026, Syndax Pharmaceuticals, Inc. (SNDX) generated trailing twelve-month (TTM) revenue of $217.2 million, reflecting explosive growth of +223.6% year-over-year. The most recent quarter (Q1 2026) recorded $64.9 million in revenue, down 5.3% sequentially.
Historical Growth Trajectory
SNDX's 5-year compound annual growth rate (CAGR) stands at +157.7%, indicating outstanding long-term growth trajectory. Syndax Pharmaceuticals, Inc.'s highest annual revenue of $172.4 million was recorded in 2025, an all-time high.
Revenue by Segment
SNDX's revenue is primarily driven by Net Product Revenues (72%), Collaboration revenue (25%), and Milestone Revenue (3%). With over half of revenue concentrated in Net Product Revenues, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including KYMR (-12.6% YoY), and TGTX (+81.3% YoY) — SNDX has outperformed the peer group in revenue growth. Compare SNDX vs KYMR →
SNDX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SNDXCurrent | $217M | +223.6% | +157.7% | -158.4% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
SNDX Historical Revenue Data (2011–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $172.4M | +627.8% | $165.4M | 96.0% | $-273,084,000 | -158.4% |
| 2024 | $23.7M | - | $22.9M | 96.5% | $-339,672,000 | -1434.4% |
| 2023 | $0 | - | $0 | - | $-229,954,000 | - |
| 2022 | $0 | -100.0% | $0 | - | $-151,757,000 | - |
| 2021 | $139.7M | +9109.6% | $139.7M | 100.0% | $26.2M | 18.8% |
| 2020 | $1.5M | +0.0% | $1.5M | 100.0% | $-71,423,000 | -4708.2% |
| 2019 | $1.5M | +0.0% | $1.5M | 100.0% | $-57,539,000 | -3792.9% |
| 2018 | $1.5M | -28.0% | $1.5M | 100.0% | $-75,876,000 | -5001.7% |
| 2017 | $2.1M | +72.8% | $2.1M | 100.0% | $-61,954,000 | -2939.0% |
| 2016 | $1.2M | +94.6% | $1.2M | 100.0% | $-43,766,000 | -3587.4% |
| 2015 | $627K | - | $627K | 100.0% | $-20,513,000 | -3271.6% |
| 2014 | $0 | - | $0 | - | $-21,332,000 | - |
| 2013 | $0 | - | $0 | - | $-8,571,000 | - |
| 2012 | $0 | - | $0 | - | $-8,734,000 | - |
| 2011 | $0 | - | $-51,000 | - | $-9,623,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SNDX — Frequently Asked Questions
Quick answers to the most common questions about buying SNDX stock.
Is SNDX's revenue growth accelerating or slowing?
SNDX revenue growth is accelerating. TTM revenue reached $217M, up +223.6% year-over-year — ahead of the 5-year CAGR of +157.7%. This indicates the business is expanding faster than its historical baseline.
What is SNDX's revenue history from 2011 to 2026?
Syndax Pharmaceuticals, Inc. (SNDX) revenue history spans 2011 to 2026. TTM revenue as of 2026 is $217M, growing at +223.6% YoY. The 5-year CAGR is +157.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SNDX's long-term revenue growth rate (CAGR)?
Syndax Pharmaceuticals, Inc.'s 5-year revenue CAGR of +157.7% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +223.6% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SNDX.
Why does SNDX's quarterly revenue fluctuate?
SNDX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Syndax Pharmaceuticals, Inc.'s revenue data from 2011 to 2026 shows full historical quarterly detail on this page.
How is SNDX's revenue distributed by segment?
SNDX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SNDX's revenue compare to industry peers?
Syndax Pharmaceuticals, Inc. (SNDX) with TTM revenue of $217M and +223.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.